New Market Study, "Switzerland Pharmaceuticals & Healthcare Report Q2 2013", Has Been Published
While the patent cliff and the consequent availability of generic drugs, as well as price cuts on generic medicines and their increasing affordability, will work towards increasing the consumption of generic medicines in Switzerland, BMI believes the government needs to do more to alter patients' attitudes towards these drugs as this is the main growth deterrent.
View full press release